<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367098">
  <stage>Registered</stage>
  <submitdate>15/09/2014</submitdate>
  <approvaldate>22/09/2014</approvaldate>
  <actrnumber>ACTRN12614001019695</actrnumber>
  <trial_identification>
    <studytitle>Omega-3 supplements for treating dry eye disease</studytitle>
    <scientifictitle>A proof-of-concept, placebo-controlled clinical trial to compare the efficacy of different forms of omega-3 essential fatty acid supplements for treating mild-to-moderate dry eye disease</scientifictitle>
    <utrn>U1111-1161-6894</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dry eye disease</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1 (Treatment 1): triglyceride form omega-3 oral supplement (1000mg EPA + 500mg DHA per day) for three months.
Arm 2 (Treatment 2): phospholipid form omega-3 oral supplement (945mg EPA + 510mg DHA per day) for three months.
Adherence to treatment will be monitored by assessing the return of unused capsules at monthly visits. 
</interventions>
    <comparator>Arm 3 (Placebo): olive oil oral supplement (1500mg per day) for three months</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Patient symptoms: ocular surface disease index (OSDI) survey score, a quantitative and validated survey instrument to grade the severity of dry eye disease.</outcome>
      <timepoint>Change in OSDI score between Days 1 and 90.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tear osmolarity: electrolyte concentration of the tears (measured in mOsm/L using the TearLab system (TearLab Corporation Pty Ltd), which is currently considered a gold standard for dry eye assessment).</outcome>
      <timepoint>Change in tear osmolarity between Days 1 and 90.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patient symptoms: OSDI survey score (as described for primary outcome 1). </outcome>
      <timepoint>Change from Day 1 at Days 30 +/- 7, 60 +/- 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tear osmolarity: electrolyte concentration of the tears (measured in mOsm/L using the TearLab system (TearLab Corporation Pty Ltd). </outcome>
      <timepoint>Change from Day 1 at Days 30 +/- 7, 60 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tear inflammatory cytokines: concentration of cytokines (pg/ml) from basal tear samples (measured using a human multiple-CBA kit for IL-2, IL-6, IL-10, Il-17A, TNF-alpha, IFN-gamma).</outcome>
      <timepoint>Change from Day 1 at Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non-invasive tear break-up time (NITBUT): measure of tear film stability, quantified using the NKBUT (Oculus Keratograph K5) and TFSQ (Medmont E300 topographer) analysis tools.</outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tear meniscus height (TMH): measure of tear volume, quantified using the Oculus Keratograph K5 and anterior optical coherence tomography (OCT) (Topcon OCT). </outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Conjunctival and limbal redness: standard clinical assessment for anterior eye inflammation, quantified with the R-scan feature of the Oculus Keratograph K5.</outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Central corneal haze: corneal reflectivity quantified in the central cornea using transverse images captured with the Topcon OCT. </outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tear stability: standard clinical measure of TBUT using sodium fluorescein dye.</outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grading of the extent and confluence of sodium fluorescein staining of the cornea and conjunctiva using the standardised Oxford grading system. </outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grading of the extent and confluence of lissamine green staining of the cornea and conjunctiva using the standardised Oxford grading system. </outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tear production: non-stimulated tear production (measured using Schirmer strips with topical anaesthetic). </outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Meibomian gland (MG) integrity: assessed using quantitative infra-red meibography of the superior and inferior eyelids (Oculus Keratograph K5) for the extent of MG drop-out.</outcome>
      <timepoint>Change from Day 1 to Days 30 +/- 7, 60 +/- 7, 90 +/- 7.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Mild-to-moderate dry eye symptoms (OSDI score: 18-65) and tear osmolarity of at least 316mOsm/L in at least one eye</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Co-morbid ocular pathology (e.g., ocular infection, intra-ocular inflammation)
Uncontrolled systemic disease
Known or suspected allergy to fish/seafood, nuts, oil or gelatin
Current medication with oral omega-3 supplements
Contact lens wear within one month prior to Day 1 or intended wear of contact lenses over the course of the study
A systemic medical condition where omega-3 supplements are contraindicated (e.g., bleeding disorders, diabetes, atrial fibrillation, familial immunocompromise, adenomatous polyposis, liver disease.)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subject must satisfy all eligibility criteria and provide written informed consent to participate.
Eligible subjects will be enrolled and assigned in sequential order to one of the three treatment groups (olive oil, triglyceride omega-3 or phospholipid omega-3) using a participant/randomisation number sequence generated in advance that randomly assigns subjects to one of the three groups. This randomisation schedule will be generated by an independent data manager and provided to a separate independent entity responsible for labelling the investigational product.
To preserve masking, the three different types of oral supplements will be packaged in identical containers. Investigators collecting and analysing data will not be involved in the reconciliation of returned study product.</concealment>
    <sequence>An independent data manager will generate a simple random number sequence in Microsoft Excel for participant randomisation. The sequence will include equal numbers for the three treatment groups. The code will be kept by the independent data manager and made available for labelling of the investigational product by sequential participant number. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>To detect a 20% difference in outcome measures treatment and control groups, for 90% power at a confidence level of 95%, the sample size was calculated as 16 participants per group. A total 20 participants will be recruited to compensate for any drop-outs.
Repeated measures analyses of variance (RM-ANOVA) will be performed to assess for treatment effects over time.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>6/10/2014</anticipatedstartdate>
    <actualstartdate>5/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/08/2015</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>24/11/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3053 - Carlton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Melbourne</primarysponsorname>
    <primarysponsoraddress>The University of Melbourne
Parkville
Victoria, Australia 3010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Melbourne early career researcher grant (ECRG) awarded to CI: Dr Laura Downie (2014)</fundingname>
      <fundingaddress>The University of Melbourne
Parkville
Victoria, Australia 3010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dry eye disease is a common condition, affecting up to 30% of adults. Common symptoms of dry eye disease include eye irritation (e.g., burning, grittiness, scratchiness, wateriness) and/or fluctuations in vision. Currently, the main form of treatment for dry eye disease is the use of artificial tears (lubrication drops), which can assist in reducing these symptoms by supplementing the deficient tear fluid. However, as artificial tears fail to address the underlying cause of dry eye disease, for many patients they are inadequate in completely relieving symptoms. New and enhanced therapeutic treatments are therefore needed. 

Inflammation plays an important role in the development of dry eye disease. There is growing scientific evidence that dietary supplementation with omega-3 essential fatty acids, may be of benefit in reducing inflammation throughout the body, including in the eye. A well recognised source of omega-3s is fish oil, which has undergone some preliminary investigations in relation to treating dry eye disease, however further research is needed to substantiate these findings.

The aim of this proof-of-concept, single site clinical trial is to evaluate the benefit of phospholipid form omega-3 supplements for the treatment of dry eye disease, and whether this form of omega-3 provides any benefit over triglyceride omega-3s. The effects of both forms of omega-3 supplements will be compared with a control group, who will consume an olive oil supplement. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Melbourne Human Research Ethics Committee â€“ Health Sciences sub-committee</ethicname>
      <ethicaddress>Office for Research Ethics and Integrity
The University of Melbourne
Level 1, 780 Elizabeth Street,
Parkville, Victoria Australia 3010 </ethicaddress>
      <ethicapprovaldate>4/02/2014</ethicapprovaldate>
      <hrec>1341262</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Laura Downie</name>
      <address>Lecturer and Clinical Leader
Department of Optometry and Vision Sciences
Level 4  Alice Hoy Building (Bldg 162), Monash Road
The University of Melbourne
Parkville, Victoria, Australia 3010.</address>
      <phone>+613 9035 3043</phone>
      <fax>+613 9035 9905</fax>
      <email>ldownie@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Laura Downie</name>
      <address>Lecturer and Clinical Leader
Department of Optometry and Vision Sciences
Level 4  Alice Hoy Building (Bldg 162), Monash Road
The University of Melbourne
Parkville, Victoria, Australia 3010.</address>
      <phone>+613 9035 3043</phone>
      <fax />
      <email>ldownie@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Laura Downie</name>
      <address>Lecturer and Clinical Leader
Department of Optometry and Vision Sciences
Level 4  Alice Hoy Building (Bldg 162), Monash Road
The University of Melbourne
Parkville, Victoria, Australia 3010.</address>
      <phone>+613 9035 3043</phone>
      <fax />
      <email>ldownie@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>